Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Mike Cheney, NP
- Phone Number: 617-643-9720
- Email: mccheney@mgh.harvard.edu
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- University of California, San Francisco
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria:
- Postmenopausal women who are planning RYGB or SG surgery
- Men aged ≥ 50 years who are planning RYGB or SG surgery
Exclusion criteria:
- Prior bariatric surgery
- Weight = 400 lbs (due to limitations of bone imaging equipment)
- Renal disease
- Hypercalcemia or hypocalcemia
- Hypomagnesemia
- Serum 25-OH vitamin D (25OHD) < 20 ng/mL
- Hyperparathyroidism
- Liver disease (AST or ALT > 2 x upper normal limit)
- HCT < 32%
- History of malignancy (except basal cell carcinoma) in the past 1 year
- Significant cardiopulmonary disease
- Major psychiatric disease
- History of celiac disease or inflammatory bowel disease
- Excessive alcohol or substance abuse
- Paget's disease, primary hyperparathyroidism, or any other known congenital or acquired bone disease other than osteoporosis
- Current hyperthyroidism or use of levothyroxine with TSH < 0.1 uIU/mL
- Current use of loop diuretics
- Current use or use in the past 12 months of oral bisphosphonates or DMAB
- Current use or use within the past 3 months of SERMs or calcitonin
- Current use or use within the past 3 months of estrogen
- Use of testosterone therapy if dose has changed within the last 3 months, or if dose change or discontinuation is planned in the upcoming 18 months
- Any current or previous use of teriparatide, strontium, or any parenteral bisphosphonate
- Use of oral or parenteral glucocorticoids for more than 14 days within the past 6 months
- Extensive dental work involving extraction or dental implant within the past 2 months or planned in the upcoming 18 months
- DXA BMD T-score of < -3.0 at PA spine, total hip, or femoral neck
- Current use of anti-VEGF drug
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Denosumab
Denosumab 60mg subcutaneous injection every 6 months
|
Denosumab will be administered at postoperative months 1, 7, and 13
Other Names:
Zoledronic Acid 5mg will be administered intravenously at postoperative month 19
Other Names:
|
|
Placebo Comparator: Placebo
Placebo subcutaneous injection every 6 months
|
Zoledronic Acid 5mg will be administered intravenously at postoperative month 19
Other Names:
Placebo will be administered at postoperative months 1, 7, and 13
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage Change in Total Hip Bone Mineral Density
Time Frame: Pre-operative baseline to post-operative month 19
|
Pre-operative baseline to post-operative month 19
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
General Publications
- Tabira T. [Immunological abnormalities in multiple sclerosis]. No To Shinkei. 1983 Jun;35(6):535-41. No abstract available. Japanese.
- Ramirez-Lassepas M, Quinones MR. Heparin therapy for stroke: hemorrhagic complications and risk factors for intracerebral hemorrhage. Neurology. 1984 Jan;34(1):114-7. doi: 10.1212/wnl.34.1.114.
- Marina Fiol C. [Treatment of the hepatic repercussions of cholelithiasis]. Minerva Med. 1966 Jul 14;57(56):2550-2. No abstract available. Italian.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Bone Diseases
- Musculoskeletal Diseases
- Metabolic Diseases
- Nutritional and Metabolic Diseases
- Bone Diseases, Metabolic
- Amino Acids, Peptides, and Proteins
- Proteins
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Azoles
- Imidazoles
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
- Antibodies
- Immunoglobulins
- Immunoproteins
- Blood Proteins
- Serum Globulins
- Globulins
- Organophosphorus Compounds
- Organophosphonates
- Diphosphonates
- Zoledronic Acid
- Denosumab
Other Study ID Numbers
Other Study ID Numbers
- 20187525 (Other Grant/Funding Number: Amgen - Investigator Sponsored Study)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.